Corporate Finance

Pivotal data on zilurgisertib offers hope for FOP patients, as Mirum and Incyte navigate a fast-track FDA review for this groundbreaking ALK2 inhibitor.

NTT DATA's top ranking in agentic AI reveals a market pivot from pilot projects to production-ready systems, solving the 'pilot paralysis' plaguing enterprises.

With its first product launch, Daré Bioscience enters a new commercial era. But can a single probiotic launch secure the future of its ambitious pipeline?

Lamb Weston's closure of a Dutch plant isn't just a local story. It's a calculated move in a global strategy to boost efficiency and tech adoption.

A Florida biotech is using a novel gene therapy to correct aging-related errors. But the real story is its funding: a decentralized, crypto-style model.

Syndax Pharmaceuticals secures a $250M war chest via convertible notes. We decode the deal, what it means for its cancer drugs, and why it's a savvy move.

Spanish immersion leader Tierra Encantada adds a heavy-hitter to its board. What does this strategic move say about scaling a mission-driven franchise?

Global consulting firm Protiviti secures a patent for an AI system that automates tedious compliance questionnaires, but its true innovation is keeping humans in control.

A fully funded drill program in Saskatchewan's rich Athabasca Basin showcases a clever partnership and the urgent, global race for clean nuclear energy.

A new study reveals a vast spending gap across the GTHA. Is Toronto's high tab a sign of value or inefficiency? A look at the systems behind the numbers.

As CEO Vytautas Sinius delivers a final address, investors are looking past his legacy to the future under his successor, CFO Tomas Varenbergas.

Clariant's successful €500M Eurobond return signals massive investor trust. This move isn't just about debt; it's a strategic play to fund growth.

A penthouse with a 100-foot terrace over Lord's Cricket Ground seeks £10M+. A story of rare property, design history, and profound philanthropic legacy.

Jade Biosciences secures a massive $150M offering to fuel its promising drug pipeline, but the deal's pricing reveals the intense pressures of the biotech market.

Beyond dividends, Stevanato Group's recent shareholder meeting signals a deeper shift in corporate governance, modernizing for stability and trust.

ZTR's 10% distribution increase offers a tempting yield, but savvy investors must look beyond the headline rate to the fund's strategy and mechanics.

Virtus Equity & Convertible Income Fund is boosting its distribution, offering a tempting 8.6% yield. But is this a sustainable strategy or a red flag?

U-Haul's consistent dividend signals financial discipline, but a deeper look reveals a company navigating a tough housing market with its diversified strengths.

Range Impact's new $10M investment seems like a win for Appalachian reclamation. But a closer look reveals a complex web of interests tying it to a tech VC.

CrowdStrike reports record earnings and a stock split, but its true story lies in deep AI pacts with OpenAI. Is it enough to secure the AI frontier?